STK11/LKB1缺陷表型而非突变降低NSCLC免疫治疗疗效并代表STING/I型干扰素/CD8+ T细胞功能障碍
研究构建基于转录组学的STK11表型分类器,分析三项随机试验(ORIENT-11、OAK、POPLAR)及TCGA-NSCLC队列,发现STK11缺陷表型而非组织突变状态可识别ICB难治性NSCLC,并与STING/I型干扰素信号扰动及CD8+ T细胞功能障碍相关。
要点
- STK11缺陷表型而非组织STK11突变状态影响ICB疗效。
- STK11缺陷肿瘤中ICB较化疗的生存获益丢失或逆转。
- STK11缺陷肿瘤中高CD8+ T细胞浸润与ICB更差结局呈相反趋势。
核心结论
- STK11表型而非突变状态能准确识别ICB难治性NSCLC并反映免疫抑制。
研究设计与样本
- 利用选定的功能性STK11事件和LKB1蛋白数据建立基于转录组学的STK11表型分类器(STK11缺陷[-def]或STK11功能正常[-prof])。
- 分析三项程序性细胞死亡蛋白-1或程序性死亡配体1(PD-L1)抑制的NSCLC随机试验(ORIENT-11,n=171;OAK,n=699;POPLAR,n=192)的院内和Genentech/Roche数据以及癌症基因组图谱-NSCLC队列。
主要发现
- 组织STK11突变不影响ICB结局。
- STK11-def肿瘤中ICB对比化疗的生存获益丢失或逆转(死亡风险比,95%置信区间:OAK [0.97,0.69-1.35];POPLAR [1.61,0.88-2.97];ORIENT-11 [1.07,0.50-2.29]),而STK11-prof肿瘤中仍存在(死亡风险比,95%置信区间:OAK [0.81,0.66-0.99];POPLAR [0.66,0.46-0.95];ORIENT-11 [0.59,0.37-0.92])。
- 在按表型和突变状态差异分类的肿瘤中,STK11野生型/缺陷肿瘤的ICB结局显著差于STK11突变(STK11-MUT)/功能正常肿瘤(p < 0.05)。
- STK11缺陷的有害影响独立于STK11/KRAS/KEAP1状态或PD-L1表达。
- STING/干扰素-I信号在STK11缺陷肿瘤患者中受到扰动,而非在STK11-MUT肿瘤患者中。
关键数值与推荐
- STK11-def肿瘤中ICB对比化疗的死亡风险比(95%置信区间):OAK 0.97(0.69-1.35),POPLAR 1.61(0.88-2.97),ORIENT-11 1.07(0.50-2.29)。
- STK11-prof肿瘤中ICB对比化疗的死亡风险比(95%置信区间):OAK 0.81(0.66-0.99),POPLAR 0.66(0.46-0.95),ORIENT-11 0.59(0.37-0.92)。
- STK11野生型/缺陷肿瘤的ICB结局显著差于STK11-MUT/功能正常肿瘤(p < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Conflicting findings have been reported regarding the association between STK11/LKB1 mutations and immune checkpoint inhibitor (ICB) efficacy in NSCLC. It has been reported that tumors could exhibit impaired STK11/LKB1 function even without STK11 mutations. We hypothesized that STK11 phenotype rather than mutation may better stratify ICB outcomes. METHODS: Selected functional STK11 events and LKB1 protein data were leveraged to establish a transcriptomics-based classifier of STK11 phenotype (STK11-deficient [-def] or -proficient [-prof]). We analyzed in-house and Genentech/Roche's data of three randomized trials of programmed cell death protein-1 or programmed death-ligand 1 (PD-L1) inhibition in NSCLC (ORIENT-11, n = 171; OAK, n = 699; POPLAR, n = 192) and The Cancer Genome Atlas-NSCLC cohort. RESULTS: Tissue STK11 mutation did not affect ICB outcomes. However, the survival benefit of ICB versus chemotherapy were lost or reversed in STK11-def tumors (hazard ratios for death, 95% confidence interval: OAK [0.97, 0.69-1.35]; POPLAR [1.61, 0.88-2.97]; ORIENT-11 [1.07, 0.50-2.29]), while remaining in STK11-prof tumors (hazard ratios for death, 95% confidence interval: OAK [0.81, 0.66-0.99]; POPLAR [0.66, 0.46-0.95]; ORIENT-11 [0.59, 0.37-0.92]). In tumors differentially classified by phenotype and mutation status, STK11-wild-type/def tumors had significantly worse ICB outcomes than STK11-mutated (STK11-MUT)/prof tumors (p < 0.05). The deleterious impact of STK11 deficiency was independent of STK11/KRAS/KEAP1 status or PD-L1 expression. The STING/interferon-I signaling, which was previously shown to be suppressed in STK11-MUT models, was perturbed in patients with STK11-def tumors rather than those with STK11-MUT tumors. Surprisingly, whereas high CD8+ T-cell infiltration was significantly associated with prolonged survival with ICB in STK11-prof tumors (p < 0.05 for 3 trials), it predicted an opposite trend toward worse ICB outcomes in STK11-def tumors across three trials. This suggested an association between STK11 deficiency and CD8+ T-cell dysfunction, which might not be reversed by programmed cell death protein 1 or PD-L1 blockade. CONCLUSIONS: STK11 phenotype rather than mutation status can accurately identify patients with ICB-refractory NSCLC and reflect immune suppression. It can help refine stratification algorithms for future clinical research and also provide a reliable resource aiding basic and translational studies in identifying therapeutic targets.
引用
- Li A, Wang Y, Yu Z, et al. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC. J Thorac Oncol. 2023. PMID: 37495171. doi:10.1016/j.jtho.2023.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。